Oncogenic ERBB3 Mutations in Human Cancers

• Recurrent ERBB3 somatic mutations occur in colon and gastric cancers
• ERBB3 mutants with ERBB2 promote ligand-independent oncogenic signaling
• Somatic ERBB3 mutants promote tumor formation
• Targeted therapeutics block ERBB3 mutant-mediated oncogenic signaling

SummaryThe human epidermal growth factor receptor (HER) family of tyrosine kinases is deregulated in multiple cancers either through amplification, overexpression, or mutation. ERBB3/HER3, the only member with an impaired kinase domain, although amplified or overexpressed in some cancers, has not been reported to carry oncogenic mutations. Here, we report the identification of ERBB3 somatic mutations in ∼11% of colon and gastric cancers. We found that the ERBB3 mutants transformed colonic and breast epithelial cells in a ligand-independent manner. However, the mutant ERBB3 oncogenic activity was dependent on kinase-active ERBB2. Furthermore, we found that anti-ERBB antibodies and small molecule inhibitors effectively blocked mutant ERBB3-mediated oncogenic signaling and disease progression in vivo.

Graphical AbstractFigure optionsDownload high-quality image (344 K)Download as PowerPoint slide